A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

This phase 2 study is testing WU-CART-007, an off-the-shelf (donor-derived) CAR-T cell therapy that targets the CD7 protein, in people with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) that has relapsed, is not responding to treatment, or still has measurable disease after therapy. **You may be eligible if...** - You have a confirmed diagnosis of T-ALL or T-LBL per WHO classification - Your disease has relapsed, is refractory to prior treatment, or shows measurable residual disease (MRD) - You are at least 1 year old - Your physical performance score is adequate (ECOG 0-1, or Karnofsky 70+) - You have adequate organ function **You may NOT be eligible if...** - You have previously received any anti-CD7 therapy - You have severe hemolytic anemia - You have moderate to severe graft-versus-host disease (GvHD) requiring systemic treatment Talk to your doctor to see if this trial is right for you.